WS #12811
AstraZeneca reports Q2 Non-GAAP EPS beat by $1.36, raises interim dividend, reaffirms FY26 guidance; bullish for pharma sector. Three dead, several injured in shooting at Seattle food festival; suspect in custody; negative sentiment for local economy and event stocks.
AstraZeneca earnings beat
AstraZeneca reports Q2 Non-GAAP EPS beat by $1.36, raises interim dividend, reaffirms FY26 guidance; bullish for pharma sector.
Three dead, several injured in shooting at Seattle food festival; suspect in custody; negative sentiment for local economy and event stocks.